Urology Times staff

Kyzatrex is an oral testosterone replacement therapy for the treatment of adult males with conditions associated with hypogonadism.

“We saw that with each additional enrichment feature the odds of finding a germline mutation would double,” says Alexis Rompré-Brodeur, MD.

“Coordination between urology and radiation oncology, if urology is placing the device, is really critical,” says Jonathan E. Shoag, MD.

“With an increase in medical and surgical therapies in younger individuals, health care providers must discuss fertility preservation options prior to affirmation therapy,” says Niki Parikh, MD, MBA, MSBA.

“The open operation is obviously done using a single incision that is quite big,” says Khetrapal.

“I think there is still a burden on women more than on men to manage everything, all at once simultaneously. And that leads to burnout, because you're constantly feeling pulled in multiple directions,” says Amanda C. North, MD.

“UGN-102 may offer a patient-centered therapeutic approach, more patient centered than standard treatments like surgery,” says Angela M. Stover, PhD.

“Healthy Now is really committed to making access to care available to all men,” says Mohit Khera, MD, MBA, MPH.

“Each patient is different, and some patients are more challenging than others in terms of placement,” says Jonathan E. Shoag, MD.

Patients in the CheckMate-914 trial had received radical or partial nephrectomy and were at moderate or high risk of relapse.

“Twenty-five percent of advanced practice providers more or less, experienced burnout, which I think is a lot higher than we would have expected,” says Amanda C. North, MD.

The novel PET imaging agent 68GA-EMP-100 PET measures c-MET expression in renal cell carcinoma.

“What we did find is that UGN-102 did not cause decrements in patient-reported urinary symptoms, bloating, flatulence, or malaise at the primary trial end point of 3 months,” says Angela M. Stover, PhD.

In this interview, Nitya E. Abraham, MD, discusses innovations in vesicovaginal fistula repair.

“We wanted to revisit the current main indications for germline testing,” says Alexis Rompré-Brodeur, MD.

“Almost half of the participating urologists did not agree that the televisits were as satisfactory as face-to-face visits,” says Nathan Feiertag.

"I would argue most people perform complicated vesicovaginal fistula repairs that can't be reached vaginally using a robotic abdominal approach," says Nitya E. Abraham, MD.

“These are men who are suffering in silence. Many of them are too embarrassed to ever discuss their sexual health problems,” says Mohit Khera, MD, MBA, MPH.

In this interview, David Joseph, MD, discusses piloting changes to the American Board of Urology Lifelong Learning Program and how they will help diplomates stay current without requiring as much time away from their families and practices.

“We were surprised that only 43% of individuals believed fertility preservation to be important, but this could be due to the relatively low age of our respondents, with the majority being between 18 and 39 years old,” says Niki Parikh, MD, MBA, MSBA.

In this interview, Catherine Ann Matthews, MD, FACS, FACOG, discusses the resurgence of single-incision slings and outlines a clinical trial of slings that she is currently leading.

“It's really the overall excellence of a multidisciplinary program focused on improving patient outcomes,” says Daniel E. Spratt, MD.

“Survival differences can be due in part to genetic differences, but also a lot of socioeconomic issues as well,” says Ridwan Alam, MD.

“Histologic variants do express Nectin-4 and Trop-2, the targets of antibody-drug conjugates that are FDA-approved in bladder cancer,” says Fed Ghali, MD.

Ridwan Alam, MD, discusses research exploring nonclinical factors affecting overall survival in patients with renal cell carcinoma.

Fed Ghali, MD, discusses the outlook for patients with variant histology bladder cancer and how antibody-drug conjugates may provide a new treatment option in this setting.

The researchers stress the need for improved patient education prior to surgery.

In this interview, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone agonists and antagonists in prostate cancer.

“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.

The miR Sentinel molecular test uses a biostatistical algorithm to examine small noncoding RNAs isolated from urinary exosomes and determine an individual’s risk of aggressive prostate cancer.